Gene transduction of pluripotent human hematopoietic stem cells (HSCs) is necessary for successful gene therapy of genetic disorders involving hematolymphoid cells.
ulations were recovered from the marrow of the mice after 7-11 months, and individual human granulocyte-macrophage and T-cell clones were isolated and expanded ex vivo. Inverse PCR from the retroviral long terminal repeat into the flanking genomic DNA was performed on each sorted cell population. The recovered cellular DNA segments that flanked proviral integrants were sequenced to confirm identity. Three mice were found (of 24 informative mice) to contain human lymphoid and myeloid populations with identical proviral integration sites, confirming that pluripotent human HSCs had been transduced.
Pluripotent hematopoietic stem cells (HSCs) give rise to all lineages of mature blood cells. Gene transduction of human HSCs is a requisite for successful gene therapy of a variety of genetic disorders of hematolymphoid cells. In contrast to the widely demonstrated ability to transduce high percentages of pluripotent murine stem cells (1) (2) (3) (4) , large animal models and preliminary human trials have shown much lower extents of gene transfer into stem cells (5) (6) (7) (8) (9) . Thus, a key basic research goal must be to derive techniques to study gene transduction of human stem cells. Numerous studies performed with murine bone marrow have used integrated retroviral vectors as clonal tags. Because retroviral DNA integrates at random sites in the target cell chromosomes, the site of integration creates a unique restriction fragment length polymorphism containing vector sequences. The presence of the same vector integrant in cells of multiple lineages, including myeloid and lymphoid, has been used to verify that pluripotent murine stem cells could be transduced and would retain the capacity for multilineage differentiation (1) (2) (3) (4) . Similar analyses with human hematopoietic stem cells have not previously been possible due to the lack of in vitro systems for pluripotent differentiation of human cells and low-level gene transfer in initial trials of human stem cell marking (8) .
We have developed a unique model system for the growth of adult human bone marrow cells in vivo in immune-deficient
The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact. mice (beige/nude/XID, bnx). Sustained hematopoiesis from human CD34+ progenitors occurs after a single tail vein injection, by cotransplantation with human bone marrow stromal cells engineered to secrete human interleukin (IL) 3 (10) . When this model of human hematopoiesis was used to study gene transfer into human hematopoietic cells by using retroviral vectors, the presence and function of the inserted gene was consistently demonstrated in human colony-forming progenitor cells isolated from the mice after 7-11 months (10, 11) . We now report use of the bnx/human (hu) cotransplantation model to study gene transduction of pluripotent human HSCs. CD34+ progenitors from human bone marrow or granulocyte colony-stimulating factor-mobilized peripheral blood were transduced in vitro by the LN vector (12) and transplanted into bnx mice as described (11) . After engraftment periods of 7-11 months, human CD3+ lymphoid and CD33+ myeloid populations were recovered from the marrow of the mice. Individual human granulocyte-macrophage and T-cell clones were isolated by automated cell deposition (ACDU), expanded ex vivo, and screened for the presence of the LN provirus. Inverse PCR from the retroviral long terminal repeat (LTR) into the flanking DNA was then performed on each sorted cell population and vector-marked clone. The recovered cellular DNA segments that flanked proviral integrants were sequenced to confirm identity.* Three mice were found (of the 24 mice studied) to contain both human lymphoid and myeloid clones with identical proviral integration sites, confirming that pluripotent human HSCs had been transduced in vitro by the LN vector prior to transplantation. To our knowledge, these data provide the first direct evidence of retroviral-mediated transduction of human HSCs that retained the potential to differentiate into both lymphoid and myeloid progeny.
MATERIALS AND METHODS
Human Marrow Transduction. CD34+ progenitors were isolated by immunomagnetic selection from normal human bone marrow and granulocyte colony-stimulating factormobilized peripheral blood as described (11) . Use of these samples was approved by the Committee on Clinical Investigations at Childrens Hospital, Los Angeles. Cells were transduced by cell-free supernatant from the LN vector (12) with stromal support as described (11) . Producer cell lines were determined to be free of both ecotropic and amphotropic recombinant helper virus by marker rescue assay and PCR for amphotropic env. After the 72-h in vitro transduction period, Abbreviations: HSC, hematopoietic stem cell; bnx, beige/nude/XID; LTR, long terminal repeat; IL, interleukin; ACDU, automated cell deposition; neo, neomycin resistance. *The sequences reported in this paper have been deposited in the GenBank data base (accession nos. X95499 and X95500).
portions of the transduced cells were plated in methylcellulosebased colony-forming unit assay with and without the selective agent G418 to assess the extent of gene transfer into 14-day colony-forming progenitors as described (11) . The remainders of each sample were transplanted into immune-deficient mice to assess transduction of more primitive progenitors.
Mice. All studies used 6-week-old bnx homozygous mice bred at Childrens Hospital Los Angeles. Cotransplantation of transduced human progenitors and stromal cells producing IL-3 was performed as described (10 (14) . Cells were transduced by cell-free retroviral supernatant with the support of an irradiated allogeneic stromal layer as described (11) . The LN vector, which carries the bacterial neomycin-resistance (neo) gene (12) packaged by the amphotropic producer PA317, was used for all transductions. The duration of transduction was 72 h in all cases. After transduction, a portion of each cell sample was plated in the methylcellulose colony-forming assay. The average extent of transduction prior to transplantation was 35.6% colonies resistant to the selective agent G418, as reported (11) . After the in vitro transduction, each sample was cotransplanted with primary human stromal cells engineered to produce human IL-3 in 6-week-old bnx mice as described (10) . Mice were sacrificed 7-11 months later. Bone marrow was recovered from the mice, analyzed for the percentage of human CD45+ cell engraftment by flow cytometry analysis, and screened for the presence of LN provirus by PCR for the neo gene as described (10) . A total of 24 bnx mice had significant levels of human hematopoietic cell engraftment (average, 4.8% human CD45+; range, 1.8-9.9%) and had proviral neo sequences in their bone marrow (Table 1) . Human-specific colony-forming assays were plated from a portion of the recovered marrow. The average extent of G418-resistant human colonies recov- sorted by immunomagnetic selection into two populations: human CD3+ T-lymphocyte pools and human CD33+ myeloid-cell pools (Fig. 1) . Both populations were then subjected to clonal integration analysis using an inverse PCR method adapted from Rill et al. (15) (Fig. 2) . Briefly, genomic DNA from each human cell population was digested with the restriction enzyme Taq I (GIBCO/BRL). Each LTR was then on a restriction fragment of unique size, determined by the distance to the nearest Taq I recognition site in the genomic DNA flanking the provirus. The LTR-containing fragments were then self-ligated to form closed circles. PCR amplification using primer pairs complementary to the LTR directed in opposite directions around the closed circle produced a PCR product of characteristic size for each integration site. Each Moloney-based proviral vector integrant yields two PCR products, one from each LTR. The progeny of each transduced stem cell will contain the same clonotypic vector integrant and will show the same pattern of PCR products.
The results of the clonal analyses of the human myeloid and T-lymphoid populations recovered from bnx/hu mice are shown in Table 1 and Fig. 3 . Oligoclonal marking of both populations was seen in most cases. Two mice were not informative. The number of individual integrants in T lymphocytes ranged from one to four separately marked populations in each informative animal. In five mice, only the myeloid cells were marked. The number of proviral integrants in the myeloid cells ranged from 1 to 10 per animal. In the event that PCR product bands representing the integrant from both human myeloid and lymphoid cells isolated from an individual mouse appeared identical in size, DNA from each was sequenced to confirm identity (Fig. 3 ). Of 24 mice tested, 4 were confirmed to harbor engrafted human myeloid and Tlymphoid cells with identical sites of proviral integration ( Three mice were found to harbor individual human T-cell and myeloid clones with proviral integrants at the same site (Table 2) . From mouse 27B2, engrafted for 10.5 months, four individual human T-cell clones were isolated with clonal vector integration sites identical to those in five myeloid clones. An inverse PCR band of 290 bp, amplified from all nine clones, had also been amplified from the sorted human CD3+ and CD33+ pools from that mouse. The sequences of the portions of the corresponding 290-bp bands, which represented flanking cellular DNA, confirmed that the proviral integration sites were identical (Table 3) . Mouse 30B1, engrafted for 7.0 months, had six individual patterns of vector integrants among the human myeloid clones, and two among the T-cell clones. One inverse PCR band, of 520 bp, was common to clones of both lineages (one T and two myeloid), and was also present in the bulk-sorted human myeloid and lymphoid populations. Again, sequencing confirmed the identity of the bands (Fig. 4) . One mouse, 25D4, had a common integrant band in the CD3+ and CD33+ populations, which was also detected in individual myeloid clones. However, only three marked T-cell clones were expanded from that animal, and they lacked the common integrant band. It is possible that the T-cell pattern observed in the bulk CD3+ population was derived from mature vectormarked T lymphocytes that were no longer clonogenic at the time of harvest and expansion. In the bulk sorted populations from mouse 30C1, also engrafted for 7 months, only two major integrants were seen in the bulk-sorted myeloid population and one in the T-cell population (Fig. 3) . Additional patterns were uncovered by the single cell cloning. There were 11 proviral integration patterns in myeloid clones, and 4 individual patterns in T-lymphoid clones. Again, one band matched in two lymphoid and four myeloid clones, as well as in both bulksorted populations.
In the human DNA sequences (Table 3) flanking the integrated proviral LTRs, there are two instances in which the virus had integrated into unlisted human DNA and a third in which the third provirus had integrated into the gene encoding human atrial natriuretic factor, in the stem cell producing both T-lymphocyte and myeloid progeny in bnx/hu mouse 30B1. Apparently alteration of this gene did not hamper hematopoietic differentiation. The inverse PCR method, modified for analysis of small cell numbers, provides a vital technique for assessing sites of random retroviral integration.
DISCUSSION
Transduction of pluripotent human stem cells will be necessary for successful gene therapy of a variety of genetic disorders of hematopoietic cells. An essential research goal must be to derive techniques to study the transfer of genes into human stem cells. In vitro systems are inadequate for analyses of the biology and transduction of pluripotent human stem cells. Committed progenitor cells expand in the cultures, obscuring the differentiation of progeny from the rare pluripotent stem cells that may be present. Another limitation is the inability to support the simultaneous growth and differentiation of both lymphoid and myeloid lineages from one human HSC in any culture system developed to date, in contrast to success in murine systems (16 (Table 1) were all transplanted with human CD34+ progenitors from the same transduction flask. However, none of these mice had clonal integration bands in human T-lymphoid or myeloid pools that matched bands from the other mice in the same set. Finding two mice with shared vector integrant patterns among human T or myeloid populations would provide evidence that primitive progenitor cells had expanded during the 72-h in vitro transduction period, as has been shown in murine bone marrow transplant systems (18) . Among the possible explanations for lack of in vitro expansion of marked human stem cells are (i) stem cell division did not occur during the 72-h in vitro incubation, but only after the cells had been transplanted, (ii) asymmetric division of the transduced stem cell occurred, with vector integrating into only one of the two daughter cells, or (iii) asymmetric division of the transduced stem cell occurred, resulting in one pluripotent stem cell and one lineage-restricted progenitor. Further studies using human stem cell marking and long-term engraftment in xenograft systems or human recipients followed by clonal analysis (19) may further define the parameters of stem cell division.
The unique system we report here combines sustained growth and multilineage differentiation of transduced human hematopoietic stem cells with the capacity to determine clonal relationships among transduced cells by inverse PCR. This model will allow analysis of conditions to increase the frequency of gene transduction of pluripotent human HSCs, including the use of purified human stem cell populations, stimulation with novel cytokines, such as flt-3 ligand, or other gene delivery systems, such as AAV-based vectors.
